ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1415

Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study

Astrid Rasmussen1, Alan Baer2, Thomas Grader-Beck3, Margaret Beach4, Blake M. Warner5, Christopher Lessard1, A. Darise Farris1 and Robert Hal Scofield1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins, Baltimore, MD, 4NIH/NIDCR, Arlington, VA, 5National Institutes of Health, Bethesda, MD

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Sjögren's syndrome, T Cell, Therapy, complementary

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE and multiple sclerosis, Met associates with a reduction of Th17 cells and of IL-17, IL-1b, IL-6, IFN-g, and TNF-a levels, while restoring or increasing regulatory T cell (Treg) levels.  Sjögren’s Disease (SjD) is a systemic autoimmune disorder characterized by autoantibody production and lymphocytic infiltration of the exocrine glands. In SjD, T cells participate in target organ inflammation and promote B cell activation; it has been proposed that an imbalance between pro-inflammatory Th17 and T follicular helper cells and their regulatory counterparts, Treg and T follicular regulatory cells, is a key component of pathogenesis. Met-treated SjD mice showed improved salivary gland function and re-establishment of the T cell equilibrium. Based on this premise, we reviewed the impact of Met on SjD in two large independent SjD cohorts.

Methods: The clinical and serologic features of patients classified as SjD (ACR-EULAR) in the OMRF cohort were retrospectively reviewed. Cases were defined as SjD diabetic patients treated with Met (SjD-Met) at the time of evaluation (n=31). The comparison groups were 1) SjD non-diabetic, not on Met matched by age, sex, and race 1:4 to the cases (SjD-match, n=124); 2) SjD diabetic patients not treated with Met (SjD-DM-notMet, n=59); 3) All diabetic SjD, irrespective of treatment (SJD-DM, n=84); and 4) All non-diabetic SjD in the cohort (SjD-nonDM, n=375). Similar analyses were conducted in a replication cohort (NIDCR; SjD-Met (n=26) and SjD-nonDM (n=394)) and the results combined in a meta-analysis.

Results: No significant differences in sociodemographic features were observed across groups. In the OMRF discovery cohort, SjD-Met had lower salivary gland focus scores than SjD-match (1.88±1.32 vs. 3.26±2.91, p=0.0002) despite similar unstimulated salivary flow rates. These findings were replicated in the NIDCR cohort (p=0.0001) and the meta-analysis (SD mean D -0.47 [-0.76; -0.19]; p=0.001) (Fig. 1). OMRF-SjD-Met subjects had lower rates of (+) Schirmer’s and vBS than SjD-match (OR 0.40, p=0.028; and OR 0.24, p=0.004, respectively); findings were replicated in the NIDCR cohort and meta-analysis (p=0.0038 for Schirmer’s and p< 0.0001 for vBS) (Figs. 2 and 3). This pattern persisted when SjD-Met was compared to SjD-DM-notMet but the effects disappear when comparing all diabetics to non-diabetics, linking the effects with Met. The only differences that could be attributed to diabetes, since they were observed when comparing all diabetics (irrespective of treatment) to non-diabetics, were lower salivary flow volumes and higher ESR in SjD-DM (OMRF cohort).

Conclusion: Our retrospective study of two independent SjD cohorts show that SjD patients receiving Met have less extensive focal lymphocytic infiltration of the minor salivary glands and lower rates of abnormal ocular tests (Schirmer’s and vBS) than their counterparts not on Met. These results justify the design of prospective, randomized, double-blind trials of Met, an accessible and safe drug for SjD, a disease with great unmet therapeutic needs.

Supporting image 1

Fig. 1. Focus Score. A) T test of the focus score in minor salivary gland biopsy of SjD cases treated with Metformin compared to SjD cases not treated with metformin; the left panel shows the OMRF cohort, and the right panel shows the NIDCR replication cohort. B) Meta-analysis of fixed (common effects) model of the two cohorts.

Supporting image 2

Fig. 2. Schirmer’s I Test. A) T test of the Schirmer’s I test results (mm of tear saturation in 5 minutes) of SjD cases treated with Metformin compared to SjD cases not treated with metformin; the left panel shows the OMRF cohort, and the right panel shows the NIDCR replication cohort. B) Meta-analysis of fixed (common effects) model of the two cohorts.

Supporting image 3

Fig. 3. van Bijsterveld Score. A) T test of the vBS of SjD cases treated with Metformin compared to SjD cases not treated with metformin; the left panel shows the OMRF cohort, and the right panel shows the NIDCR replication cohort. B) Meta-analysis of fixed (common effects) model of the two cohorts.


Disclosures: A. Rasmussen: None; A. Baer: Bristol-Myers Squibb(BMS), 2, iCell Gene Therapeutics, 2; T. Grader-Beck: Argenx, 1, 2, Novatis, 1, 2; M. Beach: None; B. Warner: Mitobridge, Inc., a subsidiary of Astellas Bio, 2, 5, Pfizer, 2; C. Lessard: Johnson and Johnson Innovative Medicine, 2, 5, Johnson and Johnson Sjögren's Disease Advisory Board, 1; A. Farris: Johnson and Johnson Innovative Medicine, 5; R. Scofield: Johnson and Johnson Innovative Medicine, 1, Merck, 1.

To cite this abstract in AMA style:

Rasmussen A, Baer A, Grader-Beck T, Beach M, Warner B, Lessard C, Farris A, Scofield R. Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/metformin-improves-salivary-gland-infiltration-and-objective-measures-of-dry-eyes-in-sjogrens-disease-a-retrospective-observational-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metformin-improves-salivary-gland-infiltration-and-objective-measures-of-dry-eyes-in-sjogrens-disease-a-retrospective-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology